SCYNEXIS- pioneering innovative medicines to help millions of patients overcome and prevent difficult-to-treat fungal infections. Ibrexafungerp, is a broad-spectrum, oral antifungal agent representing a novel therapeutic class. Ibrexafungerp, trade name BREXAFEMME®, received FDA approval in 2021.